Takeda has entered into a $1.04 billion licensing agreement with Arrowhead Pharmaceuticals around its phase 2 therapy ARO-AAT, which was designed to treat alpha-1 antitrypsin-associated liver disease.
The therapy was designed to reduce the production of mutant alpha-1 antitrypsin protein, which progresses the liver disease.
Takeda and Arrowhead will co-develop the therapy. If approved, Takeda will lead commercialization efforts and split potential profits in a 50/50 structure.
Arrowhead will receive an upfront payment of $300 million, with the potential to earn $740 million in regulatory and commercial milestones.